Recent Finacing
Recent Raise
PathoVax, a Johns Hopkins–born biotech, is developing RGVax, a vaccine candidate designed to protect against all cancer-causing human papillomavirus (HPV) types.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at PathoVax.
